8 results about "Rifampicin" patented technology

This invention belongs to the field of electroluminescence technology, specifically relating to a method for preparing a high-entropy MOF material and its application in the electrochemiluminescence detection of rifampicin. The high-entropy MOF material is a pentagonal high-entropy MOF material (HE-ATA) synthesized from metal nitrates of Fe, Co, Cu, Cr, and Zn and ATA as raw materials. This invention yields a HE-ATA catalyst with simple raw materials, convenient synthesis, and excellent electrochemiluminescence performance. It exhibits chemical stability and a multi-electron reaction potential that accelerates the conversion of dissolved oxygen to reactive oxygen species (ROS), enhancing the electroluminescence intensity. Based on the quenching effect of RIF, a method for detecting RIF using a luminol / HE-ATA system was established. By fitting the change in ECL intensity with RIF concentration, a linear calibration curve with a correlation coefficient of 0.996 and a detection limit of 3.3 × 10⁻⁶ was obtained. ‑6 µM (S / N=3). This material exhibits good sensitivity, stability, and reproducibility in the electrochemiluminescence detection of RIFs, providing a new approach for designing novel electrocatalysts for RIF detection.

This invention relates to a compound antibacterial agent and its application in open plant tissue culture. The active ingredients of the compound antibacterial agent include rifampin, kasugamycin, ticarcillin sodium clavulanic acid, and tetrachloroisophthalonitrile. The compound antibacterial agent can synergistically inhibit Agrobacterium rhizogenes or Rhodotorula glutinis, contaminating bacteria that are easily generated during plant tissue culture.

The application belongs to the technical field of biomedicine, and discloses a method for constructing a Channa argus bile stasis model. The application discloses application of rifampicin or a pharmaceutically acceptable salt thereof in construction of a fish liver injury model. The application discloses, for the first time, that the antibiotic rifampicin widely used in aquaculture is used to construct a fish liver injury model. The model is closer to the real scene of the use of a large amount of drugs when bacterial diseases break out in production practice. The injury type of the fish liver injury model is clearly directed to bile stasis, which fills the research blank of the disease model of the fish, and is different from common hepatocyte necrosis or fatty liver models.

This invention discloses a method for introducing exogenous genes into Gynostemma pentaphyllum, comprising: S1: Selecting Gynostemma pentaphyllum seeds with seed coats within 3 months of harvest, disinfecting, and culturing to obtain aseptic seedlings from seedlings, or selecting stem segments with axillary buds after leaf removal, disinfecting, and culturing using a subculture proliferation medium containing cephalosporin to obtain aseptic rooted seedlings; S2: Selecting the aseptic seedlings or aseptic cuttings obtained in S1, culturing in a rooting medium containing cephalosporin to obtain aseptic rooted seedlings; S3: Transforming plasmid Pcambia1301-PMI into Agrobacterium and culturing in a medium containing kanamycin and rifampin to obtain an Agrobacterium resuspension; S4: Infecting the aseptic rooted seedlings obtained in S2 with the Agrobacterium resuspension, and performing co-culture, antibacterial culture, and screening culture to obtain transgenic adventitious shoots. This invention can successfully introduce exogenous genes into Gynostemma pentaphyllum, obtaining Gynostemma pentaphyllum positive plants.

The application belongs to the technical field of medicine, and discloses application of genistein in preparation of medicine for resisting Mycobacterium tuberculosis. The application discloses application of genistein or a pharmaceutically acceptable derivative thereof in inhibition of Mycobacterium tuberculosis or preparation of products for resisting Mycobacterium tuberculosis. Experiments show that the MIC of genistein to M. tb H37Rv ΔleuΔpan and M. tb M. tb M. tb M. tb M. tb H37Ra is 0.03 mg / mL, and under the action of 30 μg / mL genistein, the minimum inhibitory concentration of a rifampicin-resistant strain is reduced from 50 μg / mL to 6.25 μg / mL, which greatly improves the sensitivity of the drug-resistant strain to rifampicin. Therefore, genistein can be used in preparation of medicine for resisting Mycobacterium tuberculosis or resisting tuberculosis alone, and can also be used as an auxiliary medicine for other anti-tuberculosis medicines for combined use, that is, the types of anti-tuberculosis medicines are widened and the course of treatment of tuberculosis is expected to be shortened.

The application discloses a preparation method of a dual-function antibacterial and anti-inflammatory absorbable coating material, which comprises the following steps: (1) blending rifampicin, artemisinin and an absorbable polymer A with a mixed solvent to obtain coating solution A; blending minocycline hydrochloride, aspirin and an absorbable polymer B with the mixed solvent to obtain coating solution B; the mixed solvent is selected from hexafluoroisopropanol and ethyl acetate; (2) uniformly spraying the coating solution A and the coating solution B on the surface of a degradable substrate by ultrasonic spraying, and performing drying treatment to obtain the dual-function antibacterial and anti-inflammatory absorbable coating material. According to the preparation method, the proportion of antibiotic active ingredients, anti-inflammatory drug active ingredients and absorbable polymers is regulated, the antibacterial and anti-inflammatory drug coating is uniformly and stably fixed on the surface of the degradable substrate by ultrasonic spraying, and the dual-function absorbable antibacterial and anti-inflammatory coating material with controllable release is prepared by optimizing process parameters.

This invention discloses a method for altering the reproductive pattern of *Trichogramma pseudooligophthalmus*. The method includes treating *Trichogramma pseudooligophthalmus* that is fully engaged in parthenogenesis with a rifampicin-honey aqueous solution at a concentration of 0.1-0.5 mg / ml. After treatment, the *Trichogramma pseudooligophthalmus* is used to parasitize brown planthopper eggs to obtain male F1 generation *Trichogramma pseudooligophthalmus*. This invention provides a model for exploring the reproductive methods of *Wolbachia* in hymenoptera, lays the foundation for further exploration of the reproductive patterns of *Trichogramma pseudooligophthalmus*, and also provides a model for the removal of endosymbiotic bacteria in other arthropods.

The application discloses application of bicyclic phloroglucinols in preparation of antibacterial drugs, and relates to the technical field of medicines.Bicyclic phloroglucinols (BPs) synthesized based on the skeleton of natural phloroglucinols have universal inhibitory activity on gram-positive bacteria, and the BPs can effectively reduce the effective concentration of common antibiotics (vancomycin, norfloxacin, meropenem, erythromycin and rifampicin) on bacteria, enhance the antibacterial effect of the antibiotics, and expand the antibacterial spectrum of the antibiotics. S. aureus The BPs involved in the application have the advantages of brand-new structure, high antibacterial activity, synergistic effect when combined with antibiotics, and the like, have great potential to be prepared into antibacterial drugs, and have high commercial potential.